Skip to main
KRRO
KRRO logo

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio Inc's increased research and development (R&D) expenses, rising by 23% to $21.0 million from $17.1 million the previous year, are indicative of the company's commitment to advancing its innovative pipeline of RNA editing therapies, which positions it favorably within the biopharmaceutical sector. The potential for successful outcomes from ongoing phase I/II/III clinical studies represents a significant catalyst for the company's stock, as positive developments could enhance investor confidence and market interest. Despite facing competition from larger firms with more resources and experience, Korro Bio's unique focus on RNA editing technology offers a promising avenue for expanding genetic medicine applications, which can lead the company to carve out a competitive niche.

Bears say

Korro Bio Inc faces significant challenges that contribute to a negative financial outlook, primarily due to potential inferior pharmacologic profiles of its therapies compared to existing treatments, which could hinder marketability and return on investment. The company is forecasted to require additional capital before achieving profitability, raising concerns about its ability to secure favorable financing under volatile market conditions inherent in the biotech sector. Additionally, the outcomes of ongoing and future clinical trials remain uncertain, with possible adverse effects on stock performance if regulatory authorities challenge the company’s data interpretations or if clinical endpoints are not met.

KRRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, KRRO has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $93, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $93, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.